Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti-infective skin replacement therapy - Stratatech

Drug Profile

Anti-infective skin replacement therapy - Stratatech

Alternative Names: ExpressGraft™ - Anti-microbial; ExpressGraft™ - C9T1; NIKSC9T1

Latest Information Update: 28 Mar 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Wisconsin Alumni Research Foundation
  • Developer National Institute of Diabetes and Digestive and Kidney Diseases; Stratatech
  • Class Cell therapies
  • Mechanism of Action Cathecilidin expression stimulants; Tissue replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Diabetic foot ulcer; Varicose ulcer

Most Recent Events

  • 28 Mar 2021 No recent reports of development identified for phase-I development in Diabetic-foot-ulcer(In the elderly, In adults) in USA (Topical, Patch)
  • 14 Jan 2021 Stratatech terminates a phase I trial for Diabetic foot ulcer (In adults, In the elderly) in USA due to business decision not related to product quality or safety concerns (NCT04134143)
  • 07 Nov 2019 Stratatech initiates enrolment in a phase I trial for Diabetic foot ulcer (In adults, In the elderly) in USA (NCT04134143)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top